Trial Profile
Gefitnib monotherapy in patients with post-operative recurrent non-small-cell lung cancer with the EGFR mutation: a Phase II study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jun 2009 New trial record.